HK Stock Market Move | AIM VACCINE (06660) now rises by over 5%; the company plans to apply for a listing on the North Stock Exchange. The world's first serum-free rabies vaccine is about to be launched.

AIM VACCINE (06660) has risen by over 5%, with an increase of 5.17% to HK$3.05 as of the time of reporting, with a turnover of HK$9.4029 million. In terms of news, on March 30th, the board of directors of AIM VACCINE approved plans to issue no more than 40 million shares of domestic stock, accounting for approximately 3.2611% of the total number of shares issued by the company before this issuance, and is planning to list the domestic shares on the national stock transfer system, and further apply for listing on the Beijing Securities Exchange. Public information shows that AIM VACCINE has a total of 20 vaccines under research with 24 clinical trial approvals, and the company is steadily expanding its product portfolio. In January of this year, the company's globally first developed serum-free iterative rabies vaccine successfully passed on-site inspections of clinical drug trials and drug registration production sites; currently, there is no serum-free rabies vaccine approved and marketed globally, and this product is expected to fill a market gap once it is launched. In addition, a number of heavy-hitting products such as a 23-valent pneumococcal vaccine and a novel high-efficiency human diploid rabies vaccine using new processes are also on the verge of fruition.